Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor

Thrombosis and Haemostasis

Volumn 97, Issue 4, 2007, Pages 650-657

  Vilahur, Gemma ^a   Pena, Esther ^a   Padró, Teresa ^a   Badimon, Lina ^a  

^a CSIC   (Spain)

Author keywords

Nitric oxide; Platelets; Thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; COLLAGEN; LA 419; NITRIC OXIDE; NITRIC OXIDE DONOR; PLACEBO; PROTEIN DISULFIDE ISOMERASE; PURINE P2Y12 RECEPTOR; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HEMODYNAMICS; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SWINE; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; ISOSORBIDE DINITRATE; NITRIC OXIDE; NITRIC OXIDE DONORS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN DISULFIDE-ISOMERASE; PROTEOMICS; RANDOM ALLOCATION; RECEPTORS, PURINERGIC P2; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SWINE; THROMBOSIS; TICLOPIDINE; VASODILATOR AGENTS;

EID: 34247254410     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-11-0652     Document Type: Article

References (41)

1. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-548S.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
3. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
4. Curtin R, Cox D, Fitzgerald D. Clopidogrel and ticlopidine. Michelson AD, editor. Platelets. Amsterdam: Academic Press 2002: 787-801.
5. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii-iv, xv-xvi, 1-141.
6. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41: 159-168.
7. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107: 45-49.
8. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-1164.
9. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
10. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338: 520-531.
11. International patent number WO 00/20420. Intellectual property world organization. Derivatives of isosorbid mononitrate as vasodilator agents with reduced tolerance.
12. Vilahur G, Segales E, Casani L, et al. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost 2004; 91: 1035-1043.
13. Maree AO, Cox D. Thrombosis and nitric oxide donor drugs. Thromb Haemost 2004; 91: 848-850.
14. Badimon L, Turitto V, Rosemark JA, et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-718.
15. Vilahur G, Segales E, Salas E, et al. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow and lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004; 110: 1686-1693.
16. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-1144.
17. Badimon L, Badimon JJ, Galvez A, et al. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-320.
18. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998; 19: 1538-1546.
19. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-1932.
20. Galvez A, Badimon L, Badimon JJ, et al. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 1986; 56: 128-132.
21. Molloy M, Herbert B, Walsh B, et al. Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 1998; 19: 837-844.
22. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol 1998; 18: 738-746.
23. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 5: 156-163.
24. Kaul S, Naqvi TZ, Fishbein MC, et al. Local delivery of an ultra-short-acting nitric oxide-releasing compound, DMHD/NO, is highly effective in inhibiting acute platelet-thrombus formation on injured arterial strips. J Cardiovasc Pharmacol Ther 1997; 2: 181-194.
25. Tomasiak M SH, Rusak T, Wysocka J. Nitric oxide and platelet energy metabolism. Acta Biochim Pot 2004; 51: 789-803.
26. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
27. Danielewski O, Schultess J, Smolenski A. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 2005; 93: 319 325.
28. Schafer A, Wiesmann E Neubauer S, et al. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004; 109: 1819 1822.
29. Massberg S, Gruner S, Konrad I, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-142.
30. Eigenthaler M, Nolte C, Halbruegge M, et al. Concentration and regulation of cyclic nucleotides, cyclicnucleotide-dependent protein kinases and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205: 471481.
31. Aszódi A, Pfeifer A, Ahmad M, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
32. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002-2012.
33. Keh D, Thierne A, Kurer I, et al. Inactivation of platelet glycoprotein Ilb/IlIa receptor by nitric oxide donor 3-morpholino-sydnonimiDe. Blood Coagul Fibrinolysis 2003; 14: 327-334.
34. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655-662.
35. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112.
36. Lam JY, Chesebro JH,Fuster V Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. Circulation 1988; 178: 712-716.
37. Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 1995; 86: 2168-2173.
38. Lahav J, Wijnen EM, Hess O, et al. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. Blood 2003; 102: 2085-2092.
39. Garcia Moll M. Principles and rules of the use of nitrates. Ann Cardiol Angeiol (Paris) 1997; 46: 399-405.
40. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
41. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.